http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2008115454-A
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate | 2006-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2009-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | RU-2008115454-A |
titleOfInvention | ANTI-TUMOR COMBINATIONS WITH MTOR INHIBITORS, HERCEPTIN AND / OR HKI-272 |
abstract | 1. A method of treating a neoplasm associated with overexpression or amplification of HER2 in a mammal in need of said treatment, comprising administering to said mammal an effective amount of a combination of active components containing herceptin, an mTOR inhibitor and / or HKI-272. ! 2. The method according to claim 1, characterized in that the combination contains HKI-272. ! 3. The method according to claim 1 or 2, characterized in that one or more active components are administered in subtherapeutically effective amounts. ! 4. A method of treating a neoplasm associated with an overexpression or amplification of HER2 in a mammal in need of said treatment, comprising administering to said mammal an effective amount of a combination comprising rapamycin and HKI-272. ! 5. The method according to any one of claims 1 to 2 or 4, characterized in that the neoplasm is selected from the group comprising various types of lung cancer, including bronchoalveolar carcinoma and non-small cell lung cancer, various types of breast cancer, various types of prostate cancer, myeloma , head and neck cancer, or transitional cell carcinoma; small cell and large cell neuroendocrine carcinoma of the cervix. ! 6. The method according to any one of claims 1 to 2 or 4, characterized in that the combination further comprises another active component selected from the group comprising one or more antitumor alkylating agents, one or more antitumor antimetabolic agents, one or more biochemical immunomodulators , imatinib, one or more EGFR inhibitors, a multikinase inhibitor targeted at serine / threonine and tyrosine kinase receptors |
priorityDate | 2005-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 95.